# A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

> **NCT01832506** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** MSC2156119J

## Key facts

- **NCT ID:** NCT01832506
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-30
- **Primary completion:** 2014-03-31
- **Final completion:** 2014-10-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832506, "A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01832506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*